Juvenile Idiopathic Arthritis

Pipeline Programs

Companies

Clinical Trials

2 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

764%

Small Molecule

436%

+ 7 programs with unclassified modality

On Market (3)

Approved therapies currently available

XELJANZ XRApproved

tofacitinib

Pfizer

oral2016

586M Part D

XELJANZApproved

tofacitinib

Pfizer

oral2020

280M Part D

HUMIRAApproved

adalimumab

AbbVie

2002

258M Part D

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

PfizerNEW YORK, NY

3 programs

CP-690,550Phase 31 trial

GenotropinPhase 31 trial

TofacitinibPhase 2/3Small Molecule1 trial

Active Trials

NCT01500551Completed302Est. Feb 2025

NCT02592434Completed225Est. May 2019

NCT00420251Completed50Est. Jul 2006

AbbVieNORTH CHICAGO, IL

2 programs

AdalimumabPhase 3Monoclonal Antibody

adalimumabN/AMonoclonal Antibody1 trial

Active Trials

NCT00783510Completed849Est. Feb 2024

AmgenTHOUSAND OAKS, CA

1 program

800 mg ibuprofen/26.6 mg famotidinePhase 41 trial

Active Trials

NCT01563185Completed12Est. Mar 2015

Prevail TherapeuticsNY - New York

2 programs

BaricitinibPhase 3Small Molecule1 trial

Active Trials

NCT03773978Completed220Est. Jan 2022

NCT03773965Recruiting190Est. Jul 2031

Ono PharmaceuticalJapan - Osaka

1 program

AbataceptPhase 31 trial

Active Trials

NCT01835470Completed23Est. Jul 2018

UNION therapeuticsDenmark - Hellerup

1 program

GenakumabPhase 1Monoclonal Antibody1 trial

Active Trials

NCT04337437Unknown40Est. Sep 2020

AstraZenecaCAMBRIDGE, United Kingdom

1 program

naproxenPhase 11 trial

Active Trials

NCT01358383Completed28Est. Jun 2011

RocheSTAVANGER NORWAY, Norway

2 programs

TocilizumabPHASE_1Monoclonal Antibody5 trials

TocilizumabPHASE_4Monoclonal Antibody

Active Trials

NCT07334379Recruiting60Est. Feb 2027

NCT04363853Active Not Recruiting200Est. Dec 2027

NCT04445272Completed495Est. Dec 2020

+2 more trials

GenentechCA - Oceanside

1 program

Biological DMARDsN/A1 trial

Active Trials

NCT02784808Completed4,557Est. Dec 2012

ParexelMA - Boston

1 program

GivinostatN/ASmall Molecule1 trial

Active Trials

NCT01557452Terminated1Est. Jan 2014

SandozAustria - Kundl

1 program

SecukinumabN/AMonoclonal Antibody1 trial

Active Trials

NCT06431750Not Yet Recruiting150Est. Aug 2028

Alliance PharmaceuticalsUK - Wiltshire

1 program

Teens Taking ChargeN/A1 trial

Active Trials

NCT01011179Completed46Est. Jun 2009

RegeneronTARRYTOWN, NY

1 program

SarilumabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Amgen800 mg ibuprofen/26.6 mg famotidine

RocheTocilizumab

Prevail TherapeuticsBaricitinib

PfizerCP-690,550

Ono PharmaceuticalAbatacept

PfizerGenotropin

PfizerTofacitinib

RocheTocilizumab

UNION therapeuticsGenakumab

AstraZenecanaproxen

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 7,513 patients across 20 trials

NCT01563185 Amgen800 mg ibuprofen/26.6 mg famotidine

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

Start: Apr 2012Est. completion: Mar 201512 patients

Phase 4Completed

NCT01752335 RocheTocilizumab

Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis

Start: Dec 2011Est. completion: Mar 201728 patients

Phase 4Unknown

NCT03773965 Prevail TherapeuticsBaricitinib

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Start: Apr 2019Est. completion: Jul 2031190 patients

Phase 3Recruiting

NCT03773978 Prevail TherapeuticsBaricitinib

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Start: Dec 2018Est. completion: Jan 2022220 patients

Phase 3Completed

NCT02592434 PfizerCP-690,550

Efficacy Study Of Tofacitinib In Pediatric JIA Population

Start: Jun 2016Est. completion: May 2019225 patients

Phase 3Completed

NCT01835470 Ono PharmaceuticalAbatacept

Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

Start: Aug 2013Est. completion: Jul 201823 patients

Phase 3Completed

NCT00420251 PfizerGenotropin

Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

Start: Mar 1996Est. completion: Jul 200650 patients

Phase 3Completed

NCT01500551 PfizerTofacitinib

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Start: Mar 2013Est. completion: Feb 2025302 patients

Phase 2/3Completed

NCT07334379 RocheTocilizumab

Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study

Start: Oct 2025Est. completion: Feb 202760 patients

Phase 2Recruiting

NCT04363853 RocheTocilizumab

Tocilizumab Treatment in Patients With COVID-19

Start: Jun 2020Est. completion: Dec 2027200 patients

Phase 2Active Not Recruiting

NCT04445272 RocheTocilizumab

Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia

Start: May 2020Est. completion: Dec 2020495 patients

Phase 2Completed

NCT03046381 RocheTocilizumab

Tocilizumab in Patients With Schnitzler's Syndrome

Start: Jul 2017Est. completion: Apr 20198 patients

Phase 2Completed

NCT02676947 RocheTocilizumab

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Start: Jan 2016Est. completion: Feb 201829 patients

Phase 2Completed

NCT04337437 UNION therapeuticsGenakumab

Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers

Start: Apr 2019Est. completion: Sep 202040 patients

Phase 1Unknown

NCT01358383 AstraZenecanaproxen

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

Start: May 2011Est. completion: Jun 201128 patients

Phase 1Completed

NCT06431750 SandozSecukinumab

Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

Start: Apr 2025Est. completion: Aug 2028150 patients

N/ANot Yet Recruiting

NCT01557452 ParexelGivinostat

Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Start: Dec 2011Est. completion: Jan 20141 patients

N/ATerminated

NCT01011179 Alliance PharmaceuticalsTeens Taking Charge

Internet Self-Management Program With Telephone Support for Adolescents With Arthritis

Start: Nov 2008Est. completion: Jun 200946 patients

N/ACompleted

NCT00783510 AbbVieadalimumab

Juvenile Idiopathic Arthritis (JIA) Registry

Start: Jul 2008Est. completion: Feb 2024849 patients

N/ACompleted

NCT02784808 GenentechBiological DMARDs

Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)

Start: Jan 2000Est. completion: Dec 20124,557 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals

2 actively recruiting trials targeting 7,513 patients

18 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.